{"analyses":[{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by geographic region (East Asia vs. non-East Asia), ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%) and histology (squamous vs. non-squamous).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2134","pValueComment":"One-sided p-value based on stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.94","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"7.4","value":"6.2"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"8.0","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"405"}],"units":"Participants"}],"description":"PFS was determined for participants with a TPS of ≥20% and was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The efficacy hypothesis was analyzed using a sequential testing strategy that involved testing a hypothesis only if the superiority of pembrolizumab over chemotherapy was established for all the preceding hypotheses. The order of testing was PFS in participants with TPS≥50%, then with TPS≥20%, and finally with TPS≥1%. The PFS for participants with a TPS ≥20% is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles)","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W","id":"OG001","title":"Chemotherapy (SOC Treatment)"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%.","reportingStatus":"POSTED","timeFrame":"Up to approximately 44 months","title":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%","type":"SECONDARY","unitOfMeasure":"Months"}